Kangfang Biotech (09926) issued an announcementbigspincasino, China's State Drug Administration has approved the company's independent research and developmentbigspincasinoThe world's first new drug for bispecific antibody, Idarfang ® (Evosil Injector, PD-1/ VEGF), is a new drug marketing application for combination chemotherapy for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer with EGFR mutations that progress after treatment with epidermal growth factor receptor tyrosine stimulation inhibitors.

The NMPA approval for marketing of Idarfang ® is based on AK112 - 301/ HARMONi-A (CTR20213079), a randomized, double-blind, multicenter phase III clinical study conducted in China. The primary endpoint of the study is progression-free survival (PFS) and the secondary endpoint is overall survival (OS).